Physician profile
Sandra Erickson
NPI 1437112315
$6,507.47
in general payments reported to CMS, 2019-2025
21 companies · $51.12 in 2025
The $51.12 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,335 · 2022: $417 · 2023: $3,942 · 2024: $762 · 2025: $51.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,298 · Travel and Lodging: $2,188 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,297.66 |
| Travel and Lodging | $2,187.68 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $269.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $2,074.94 | 2023 | Intracept |
| Nevro Corp. | $1,952.58 | 2021-2024 | Senza |
| Abbott Laboratories | $764.36 | 2021-2022 | |
| Abbvie INC. | $406.74 | 2023-2025 | |
| Medtronic, INC. | $352.51 | 2023-2024 | Intellis Adaptivestim, Synchromedii, Accurian |
| Boston Scientific Corporation | $277.19 | 2021-2024 | Intracept |
| Spr Therapeutics, INC | $101.03 | 2023 | Sprint Pns System |
| Allergan, INC. | $89.43 | 2021 | |
| Nalu Medical, INC. | $82.63 | 2021-2024 | Nalu Neurostimulation System |
| Almatica Pharma LLC | $81.93 | 2021 | |
| Ibsa Pharma INC. | $52.32 | 2021 | |
| Collegium Pharmaceutical, INC. | $42.98 | 2021 | |
| Lilly USA, LLC | $36.66 | 2025 | Zepbound, Mounjaro |
| Vertex Pharmaceuticals Incorporated | $36.27 | 2024 | |
| Merz Pharmaceuticals, LLC | $34.83 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $28.75 | 2023 | Prialt |
| Averitas Pharma INC. | $24.57 | 2023 | Qutenza |
| Biodelivery Sciences International, INC. | $18.71 | 2021 | |
| Pfizer INC. | $16.57 | 2021 | |
| Radius Health, INC. | $16.27 | 2024 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Erickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.